Use of electronic cigarettes leads to significant beta2-nicotinic acetylcholine receptor occupancy: Evidence from a PET imaging study

Nicotine and Tobacco Research

Volumn 20, Issue 4, 2018, Pages 425-433

  Baldassarri, Stephen R ^a   Hillmer, Ansel T ^a   Anderson, Jon Mikael ^a   Jatlow, Peter ^a   Nabulsi, Nabeel ^a   Labaree, David ^a   Cosgrove, Kelly P ^a   O'Malley, Stephanie S ^a   Eissenberg, Thomas ^b   Krishnan Sarin, Suchitra ^a   Esterlis, Irina ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUBATINE F 18; NICOTINE; NICOTINIC RECEPTOR BETA2; TRACER; UNCLASSIFIED DRUG; NICOTINIC RECEPTOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; BLOOD NICOTINE LEVEL; CIGARETTE; CIGARETTE SMOKING; CONTROLLED STUDY; DRUG CRAVING; ELECTRONIC CIGARETTE; FEMALE; HUMAN; IN VIVO STUDY; MALE; MAXIMUM CONCENTRATION; MIDDLE AGED; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; TIME TO MAXIMUM PLASMA CONCENTRATION; TOBACCO CIGARETTE; BRAIN; DIAGNOSTIC IMAGING; DRUG EFFECT; METABOLISM; PROCEDURES; SMOKING; TOBACCO; TOBACCO DEPENDENCE;

ADULT; BRAIN; ELECTRONIC NICOTINE DELIVERY SYSTEMS; FEMALE; HUMANS; MALE; NICOTINE; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, NICOTINIC; SMOKING; TOBACCO; TOBACCO USE DISORDER;

EID: 85043589607     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/ntx091     Document Type: Article

References (47)

1. National Center for Chronic Disease P, Health Promotion Office on S, Health. Reports of the Surgeon General. The Health Consequences of Smoking-50 Years of Progress: A Report of the Surgeon General. Atlanta (GA): Centers for Disease Control and Prevention (US); 2014.
2. Cahill K, Stevens S, Lancaster T. Pharmacological treatments for smoking cessation. JAMA. 2014;311(2):193-194.
3. Henningfield JE, Stapleton JM, Benowitz NL, Grayson RF, London ED. Higher levels of nicotine in arterial than in venous blood after cigarette smoking. Drug Alcohol Depend. 1993;33(1):23-29.
4. * -nicotinic acetylcholine receptor occupancy after use of a nicotine inhaler. Int J Neuropsychopharmacol. 2011;14(3):389-398.
5. McRobbie H, Bullen C, Hartmann-Boyce J, et al. Electronic cigarettes for smoking cessation and reduction. Cochrane Database Syst Rev 2014;12:Cd010216.
6. Eissenberg T. Electronic nicotine delivery devices: ineffective nicotine delivery and craving suppression after acute administration. Tob Control. 2010;19(1):87-88.
7. Vansickel AR, Eissenberg T. Electronic cigarettes: effective nicotine delivery after acute administration. Nicotine Tob Res. 2013;15(1): 267-270.
8. Lopez AA, Hiler MM, Soule EK, et al. Effects of Electronic Cigarette Liquid Nicotine Concentration on Plasma Nicotine and Puff Topography in Tobacco Cigarette Smokers: A Preliminary Report. Nicotine Tob Res. 2016;18(5):720-723.
9. Spindle TR, Breland AB, Karaoghlanian NV, Shihadeh AL, Eissenberg T. Preliminary results of an examination of electronic cigarette user puff topography: the effect of a mouthpiece-based topography measurement device on plasma nicotine and subjective effects. Nicotine Tob Res. 2015;17(2):142-149.
10. Ramôa CP, Hiler MM, Spindle TR, et al. Electronic cigarette nicotine delivery can exceed that of combustible cigarettes: a preliminary report. Tob Control. 2016;25(e1):e6-e9.
11. Wagener TL, Floyd EL, Stepanov I, et al. Have combustible cigarettes met their match? The nicotine delivery profiles and harmful constituent exposures of second-generation and third-generation electronic cigarette users. Tob Control. 2017;26(e1):e23-e28.
12. Hajek P, Etter JF, Benowitz N, Eissenberg T, McRobbie H. Electronic cigarettes: review of use, content, safety, effects on smokers and potential for harm and benefit. Addiction. 2014;109(11):1801-1810.
13. Breland A, Soule E, Lopez A, et al. Electronic cigarettes: what are they and what do they do? Ann N Y Acad Sci. 2017;1394(1):5-30.
14. Cosgrove KP, Batis J, Bois F, et al. beta2-Nicotinic acetylcholine receptor availability during acute and prolonged abstinence from tobacco smoking. Arch Gen Psychiatry. 2009;66(6):666-676.
15. Esterlis I, Cosgrove KP, Batis JC, et al. Quantification of smoking-induced occupancy of beta2-nicotinic acetylcholine receptors: estimation of nondisplaceable binding. J Nucl Med. 2010;51(8):1226-1233.
16. * -nicotinic acetylcholine receptors in recently abstinent tobacco smokers. Arch Gen Psychiatry. 2012;69(4):418-427.
17. Cosgrove KP, Batis J, Bois F, et al. beta2-Nicotinic acetylcholine receptor availability during acute and prolonged abstinence from tobacco smoking. Arch Gen Psychiatry. 2009;66(6):666-676.
18. Brody AL, Mandelkern MA, Costello MR, et al. Brain nicotinic acetylcholine receptor occupancy: effect of smoking a denicotinized cigarette. Int J Neuropsychopharmacol. 2009;12(3):305-316.
19. Brody AL, Mandelkern MA, London ED, et al. Cigarette smoking saturates brain alpha 4 beta 2 nicotinic acetylcholine receptors. Arch Gen Psychiatry 2006;63:907-15.
20. Carter LP, Stitzer ML, Henningfield JE, O'Connor RJ, Cummings KM, Hatsukami DK. Abuse liability assessment of tobacco products including potential reduced exposure products. Cancer Epidemiol Biomarkers Prev. 2009;18(12):3241-3262.
21. King AC, de Wit H, McNamara PJ, Cao D. Rewarding, stimulant, and sedative alcohol responses and relationship to future binge drinking. Arch Gen Psychiatry. 2011;68(4):389-399.
22. NINDS C. Structured Clinical Interview for DSM-IV Axis Disorders Patient Version (SCID-I/P). Washington, DC: American Psychiatric Press; 1996.
23. Beck AT, Ward CH, Mendelson MM, et al. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-571.
24. Radloff LS. The CES-D Scale: A Self-Report Depression Scale for Research in the General Population. Appl Psych Measure 1977;1:385-401.
25. Knight RG, Waal-Manning HJ, Spears GF. Some norms and reliability data for the State-Trait Anxiety Inventory and the Zung Self-Rating Depression scale. Br J Clin Psychol. 1983;22 (Pt 4):245-249.
26. Barratt ES, Patton J, Stanford M. Barratt Impulsiveness Scale. Texas: Barratt-Psychiatry Medical Branch, University of Texas; 1975.
27. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict. 1991;86(9):1119-1127.
28. Tiffany ST, Drobes DJ. The development and initial validation of a questionnaire on smoking urges. Br J Addict. 1991;86(11):1467-1476.
29. Toll BA, Katulak NA, McKee SA. Investigating the factor structure of the Questionnaire on Smoking Urges-Brief (QSU-Brief). Addict Behav. 2006;31(7):1231-1239.
30. Hughes JR, Hatsukami D. Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry. 1986;43(3):289-294.
31. Morean ME, de Wit H, King AC, Sofuoglu M, Rueger SY, O'Malley SS. The drug effects questionnaire: psychometric support across three drug types. Psychopharmacology (Berl). 2013;227(1):177-192.
32. Esterlis I, Cosgrove KP, Batis JC, et al. GABAA-benzodiazepine receptor availability in smokers and nonsmokers: relationship to subsyndromal anxiety and depression. Synapse. 2009;63(12):1089-1099.
33. Hugo WAMdJ, Floris HPvV, Reina WK, et al. Performance evaluation of the ECAT HRRT: an LSO-LYSO double layer high resolution, high sensitivity scanner. Phys Med Biol 2007;52:1505.
34. Carson RE, Barker WC, Liow J-S, et al. Design of a motion-compensation OSEM list-mode algorithm for resolution-recovery reconstruction for the HRRT. In: Nuclear Science Symposium Conference Record, 2003 IEEE; October 19-25, 2003; Portland, OR. p. 3281-3285.
35. Jin X, Mulnix T, Gallezot JD, Carson RE. Evaluation of motion correction methods in human brain PET imaging-a simulation study based on human motion data. Med Phys. 2013;40(10):102503.
36. Brust P, Patt JT, Deuther-Conrad W, et al. In vivo measurement of nicotinic acetylcholine receptors with [18F]norchloro-fluoro-homoepibatidine. Synapse. 2008;62(3):205-218.
37. Bois F, Gallezot JD, Zheng MQ, et al. Evaluation of [(18)F]-(-)-norchlorofluorohomoepibatidine ([(18)F]-(-)-NCFHEB) as a PET radioligand to image the nicotinic acetylcholine receptors in non-human primates. Nucl Med Biol. 2015;42(6):570-577.
38. * nicotinic acetylcholine receptors with (-)-[(18)F]Flubatine PET: Implementation of bolus plus constant infusion and sensitivity to acetylcholine in human brain. Neuroimage. 2016;141:71-80.
39. Cunningham VJ, Rabiner EA, Slifstein M, Laruelle M, Gunn RN. Measuring drug occupancy in the absence of a reference region: the Lassen plot re-visited. J Cereb Blood Flow Metab. 2010;30(1):46-50.
40. Sofuoglu M, Herman AI, Nadim H, Jatlow P. Rapid nicotine clearance is associated with greater reward and heart rate increases from intravenous nicotine. Neuropsychopharmacology. 2012;37(6):1509-1516.
41. Farsalinos KE, Spyrou A, Tsimopoulou K, et al. Nicotine absorption from electronic cigarette use: comparison between first and new-generation devices. Sci Rep 2014;4:4133.
42. Talih S, Balhas Z, Eissenberg T, et al. Effects of user puff topography, device voltage, and liquid nicotine concentration on electronic cigarette nicotine yield: measurements and model predictions. Nicotine Tob Res. 2015;17(2):150-157.
43. Dawkins LE, Kimber CF, Doig M, Feyerabend C, Corcoran O. Selftitration by experienced e-cigarette users: blood nicotine delivery and subjective effects. Psychopharmacology (Berl). 2016;233(15-16): 2933-2941.
44. Ashton H, Stepney R, Thompson JW. Self-titration by cigarette smokers. Br Med J. 1979;2(6186):357-360.
45. Rosbrook K, Green BG. Sensory Effects of Menthol and Nicotine in an E-Cigarette. Nicotine Tob Res. 2016;18(7):1588-1595.
46. Kosmider L, Sobczak A, Fik M, et al. Carbonyl compounds in electronic cigarette vapors: effects of nicotine solvent and battery output voltage. Nicotine Tob Res. 2014;16(10):1319-1326.
47. Benowitz NL. Nicotine addiction. N Engl J Med. 2010;362(24):2295-2303.